Table 4 Cardiac and vascular surgeries
From: Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review
Author and year | Comparator and patients per arm (n) | Primary endpoint | Principal results |
|---|---|---|---|
Krishnan 2009[6] | Floseal® (1,603) | Length of hospital stay | Floseal® was associated with a lower likelihood of exceeding the expected LOS compared with baseline (OR = 0.791; p < 0.01) |
Surgicel® + thrombin (17,507) | |||
Gelfoam® + thrombin (10,348) | |||
Other (7,492) | |||
Nasso 2009[9] | Floseal® (209) | Rate of successful intraoperative haemostasis and time required for haemostasis | Significantly higher rates of successful haemostasis and a shorter time to haemostasis were observed in the Floseal® group (p < 0.001 both) |
Topical haemostatic agent | |||
(Surgicel® or Gelfoam®) (206) | |||
Sugarman 2013[8] | Economic comparison with 2009 Nasso study | Economic value when using Floseal® to achieve haemostasis | The use of Floseal® resulted in substantial net cost savings. |